1. Anderson G, Maes M. Melatonin: an Overlooked Factor in Schizophrenia

and in the Inhibition of Anti- Psychotic Side Effects. Metabolic Brain

Disease. 2012;27(2): 113-119, DOI: 10.1007/s11011-012-9307-9.

 

2. Anderson G, Maes M, Berk M. Inflammation-related disorders in the

tryptophan catabolite (TRYCAT) pathway in depression and

somatization. Adv Protein Chemistry Structural Biol. 2012;88:27-48.

 

3. Anderson G, Rodriguez M. Multiple Sclerosis, Seizures and Anti-

Epileptics: Role of IL-18, IDO and Melatonin. European Journal of

Neurology. 2011 May;18(5):680-5.

 

4. Anderson G, Ojala JO. Alzheimer’s and Seizures: Interleukin-18,

Indoleamine 2,3-Dioxygenase and Quinolinic Acid.

Int.J.Trytophan Res. 2010:3 169–173 doi: 10.4137/IJTR.S4603

 

 

5. Maes M, Berk M, Goehler L, Song C, Anderson G, Galecki P, Leonard B.

Depression and sickness behavior are Janus-faced responses to shared

inflammatory pathways. BMC Medicine. 2012, 10:66 DOI:10.1186/1741-

7015-10-66

 

6. Anderson.G. Prenatal Corticosteroids: Pretermer Outcomes, Stress,

Schizophrenia, Multiple Sclerosis and the Developmental Role of

Melatonin and Vitamin D3. J Pediatr Adolesc Gynecol.2010;23(5) 317-20.

 

7. Anderson G. The role of melatonin in post-partum psychosis and

depression associated with bipolar disorder. J Perinat Med. 2010

Nov;38(6):585-7.

 

8. Anderson, G. and Brown, R. I. F. Real and laboratory gambling,

sensation-seeking and arousal. British Journal of Psychology, 75: 401–

410. doi: 10.1111/j.2044-8295.1984.tb01910.x

 

9. Anderson G. Neuronal-Immune Interactions in Mediating Stress Effects

in the Etiology and Course of Schizophrenia: Role of the Amygdala in

Developmental Co-ordination. Med. Hypotheses. 2011;76:54-60.

doi:10.1016/j.mehy.2010.08.029

 

10.Anderson G. Melatonin, Agomelatine and Alcoholism: Relevance to

Alcohol Related Brain Damage and Comorbid Psychosis. Addict.Disord

& Their Treatment. 10(2):84-90, June 2011. doi:

10.1097/ADT.0b013e3181fc095a

 

11.Dafters R, Anderson G. Conditioned tolerance to the tachycardia

effect of ethanol in humans. Psychopharmacology. ;78(4):365-7.

DOI: 10.1007/BF00433743

 

12 Rodriguez M and Anderson G. Multiple Sclerosis and

Seizures: possible role for Helicobacter pylori. Eu.J. Neuorlogy

Aug. 2011; 18:e117. doi:10.1111/j.1468-1331.2011.03453.x

 

 

13. Rodriguez M. and Anderson G. Valproate and Glioblastoma:

Role for Melatonin and Vitamin D3. Neurology. Sept.20, 2011

 

14. Anderson G, and Ojala JO. Alzheimer’s and Valproate: Role for

melatonin. Neurology Sept. 27. 2011; 77:1263 WriteClick

 

15. Anderson G. Melatonin and Cognitive Deficits in Bipolar Disorder and

Mild Cognitive Impairment. Psychotherapy Psychosomatics.

2012;81:244 (DOI:10.1159/000335247)

 

16. Anderson G. On IDO, neuroinflammation induced depression

and overlap to Alzheimer’s: Role of AHr and circadian genes.

J Alzheimer’s Disease. 2012; doi:10.3233/JAD-2011-111097

 

17. Anderson G, Maes M, Berk M. Biological Underpinnings of the

Commonalities in Depression, Somatization, and Chronic

Fatigue Syndrome. Medical Hypotheses. 2012; 78:752-756

DOI:10.1016/j.mehy.2012.02.023

 

18. Anderson G. Hemochromatosis and Bipolar Disorder. General

Hospital Psychiatry. 2012;34(4):433.

 

19. Anderson G and Brown R.I.F. Some applications of reversal

theory to the explanation of gambling and gambling addictions.

Journal of Gambling Studies:3(3) Sept. DOI:10.1007/BF01367439

 

20. Anderson G, Berk M, Maes M. Biological phenotypes underpin the physio-

somatic symptoms of somatization, depression and chronic fatigue

syndrome: Classification implications. Acta Psychiatrica Scandanavia.

2014 Feb;129(2):83-97.

 

21. Anderson G, Maes M. Schizophrenia: Linking prenatal infection to

hypoNMDAr, Immune-inflammation, demyelination, susceptibility genes,

IDO, neuroprogression and treatment. Prog NeuroPsPharm Bio Psychiatr.

2013 Apr 5;42:5-19.

 

22. Anderson G, Maes M, Berk M. Schizophrenia is primed for an increased

expression of depression through activation of immuno-inflammatory,

oxidative and nitrosative stress, and tryptophan catabolite pathways. Prog

NeuroPsPharm Bio Psychiatr. 2013 Apr 5;42:101-14.

 

23. Anderson G, Berk M, Dodd S, Bechter K, Altamura AC, Dell’Osso B,

Kanba S, Monji A, Fatemi SH, Buckley P, Debnath M, Das UN, Meyer U,

MullerN, Maes M. Immuno-inflammatory, oxidative and nitrosative stress,

and neuroprogressive pathways in the etiology, course and treatment of

schizophrenia. (Editorial). Prog NeuroPsPharm Bio Psychiatr. 2013 Apr

5;42:1-4.

 

24. Sutinen EM, Pirttilä T, Anderson G, Antero Salminen A, Ojala JO.

Pro-inflammatory interleukin-18 increases Alzheimer’s disease associated

amyloid-B production in human neuron-like cells. J Neuroinflammation.

2012 Aug 16;9:199.

 

25. Dodd S, Maes M, Anderson G, Dean O, Moylan S, Berk M. Putative

neuroprotective agents in major psychoses. Prog Neuropsychopharmacol

Biol Psychiatry. 2013;42:135-145

 

26. Morris G, Anderson G, Galecki P, Berk M, Maes M. A narrative

review on the similarities and dissimilarities between myalgic

encephalomyelitis/chronic fatigue syndrome (ME/CFS) and sickness

behavior BMC Medicine. 2013, 11:64

 

27. Anderson G, Maes M. Melatonin in the etiology, pathophysiology, and

management of Schizophrenia. Chapter in book: Melatonin and Melatonergic

Drugs in Clinical Practise. 2014 Eds: Srinvasan V, Shillcott SD, Oter S,

Brzezinski A. Publisher: Springer. ISBN: 978-81-332-0825-9

 

 

28. Anderson G, Maes M. Metabolic Syndrome, Alzheimer’s,

Schizophrenia and Depression: Role for Leptin, Melatonin,

Kynurenine Pathways and Neuropeptides. Pages: 235-48. Chapter 13 in book:

Metabolic Syndrome and Neurological Disorders. Eds: Farooqui T,

and Farooqui AA.

 

29. Maes M, Ringel, K, Kubera M, Anderson G, Morris G, Galecki P,

LeunisJ-C, Geffard M. In Myalgic Encephalomyelitis / chronic fatigue

syndrome, increased autoimmune activity against 5-HT is associated

with immuno-inflammatory pathways and bacterial translocation.

J Affective Dis. 2013 Sep 5;150(2):223-30.

 

30. Anderson G and Maes M. Postpartum Depression:

Neuropsychoimmunological Underpinnings and Treatment.

Neuropsychiatric Disease and Treatment. 2013;9:277–287.

 

31. Anderson G, Beischlag TV, Vinciguerra M, Mazzoccoli G. The

circadian clock circuitry and the AHR signaling pathway in

physiology and pathology. Biochemical Pharmacology.

2013;85:1405–1416.

 

32. Maes M, Anderson G, Morris G, Berk M. Diagnosis of

myalgic encephalomyelitis: where are we now? Expert Opinion On

Medical Diagnostics. 2013 May;7(3):221-5.

 

33. Muñoz M, Carranza A, Pavón A, Anderson G, Coveñas R.

Immunologicalizaiton of substance P and the KN-1 receptor in

Hofbauer cells in human normal placenta. Microscopy Res &

Technique. 2013;76:1310–1313 DOI: 10.1002/jemt.22303

 

34. Maes M. Anderson G, Morris G, Twisk F, Dinan. Hypothalamic-

pituitary-adrenal hypofunction in chronic fatigue spectrum disorders:

cause or consequence of activated immune-inflammatory and

oxidative and nitrosative pathways. Mol. NeuroBio. In press.

 

35. Anderson G, Maes M. Oxidative/Nitrosative Stress and Immuno-

inflammatory Pathways in Depression: Treatment Implications. Curr

Pharmaceut Design. 2014;20(23):3812-47.

 

36. Maes M, Anderson G. Classification of ME, CFS and CF, Response

to Twisk. Expert Opinion On Medical Diagnostics. In Press.

 

37. Morris G, Anderson G, Berk M, Maes M. Coenzyme Q10 depletion in

medical and neuropsychiatric disorders: Potential repercussions and

therapeutic implications. Mol Neurobiology. 2013 Dec;48(3):883-903.

 

38. Anderson G, Maes M. Neurodegeneration in Parkinson's Disease:

Interactions of Oxidative Stress, Tryptophan Catabolites and

Depression with Mitochondria and Sirtuins. Mol NeuroBio. 2014

Apr;49(2):771-83.

 

39. Anderson G, Seo M, Berk M, Carvalho AF, Maes M. Gut Permeability and Microbiota in Parkinson's Disease: Role of Depression, Tryptophan Catabolites, oxidative and nitrosative stress and the Melatoninergic Pathways. Curr Pharm Des. 2016; 22(40): 6142- 6151

 

40. Anderson G, Maes M. Redox Regulation and the Autistic Spectrum:

Role of Tryptophan Catabolites, Immuno-inflammation,

Autoimmunity and the Amygdala. Curr NeuroPharmacol. 2014

Mar;12(2):148-67.

 

41. Anderson G, Maes M. Melatonin: A Natural Homeostatic Regulator – Interactions with

Immune Inflammation and Trytophan Catabolite Pathways in the Modulation of

Migraine and Endometriosis. J. Nat. Prod. Res. Updat. 2015;1:7-17.

 

42. Anderson G, Maes M. Local Melatonin Regulates Inflammation

Resolution: A Common Factor in Neurodegenerative, Psychiatric

and Peripheral Inflammatory Disorders. CNS & Neurol Dis Dr Tar. 2014, 13, 783-793.

 

43. Anderson G, Maes M. Reconceptualizing Adult Neurogenesis: Role

for S1P and FGF1 in Co-ordinating Astrocyte-Neuronal Precursor

Interactions. CNS & Neurol Dis Dr Tar. 2014 Feb;13(1):126-36.

 

44. Anderson G, Kubera M, Duda W, Lasoń W, Berk M, Maes M. IL-6

and Depression: Role of the tryptophan catabolites, melatonin and

neuroprogression. Pharmacol Reports. 2013;65(6):1647-54.

 

45. Anderson G, Berk M, Dean O, Moylan S, Maes M. Leading Edge:

Role of immune-inflammatory and oxidative and nitrosative stress

pathways in the etiology of depression: therapeutic implications.

CNS Drugs. 2014 Jan;28(1):1-10.

 

46. Morris G, Anderson G, Maes M, Twist F. Hypothalamic-pituitary-adrenal hypofunction

in Myalgic Encephalomyelitis (ME) / Chronic Fatigue Syndrome (CFS) as a

consequence of activated immune-inflammatory and oxidative and nitrosative

pathways. Mol Neurobiol. 2016 Oct 20.

 

47. Anderson G, Maes M. Oxidative and Nitrosative Stress, Immune Inflammation and

Trptophan Catabolites in Driving Melatoninergic Pathway Alterations in Depression:

Treatment Implications. Chap in Book: The Search For Novel Anti-depressants- An

Integrative View of Drug Discovery. Bentham Press.

 

48. Anderson G, Maes M. Multiple Sclerosis: the role of Melatonin and N-acetylserotonin.

MS&Related Dis. 2015 Mar;4(2):112-23. DOI: http://dx.doi.org/10.1016/j.msard.2014.12.001

 

49. Anderson G, Beischlag TV. Mazzoccoli G.  The Kynurenine and Melatoninergic Pathways in Glioblastoma. Curr Pharm Des. 2016;22(8):1033-1048.

​

 

50. Anderson G, Jacob A, Bellivier F, Geoffroy PA. Bipolar Disorder: The Role of the

Kynurenine and Melatoninergic Pathways. Curr Pharm Des. 2016;22(8):987-1012.

 

51. Anderson G, Maes M. Schizophrenia: linking prenatal infection to

cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA

receptor hypofunction, neurodevelopment and neuroprogression.

World Biomedical Frontiers. Infections & Immunity. ISSN: 2328 0166

 

52. Moylan S, Dean O, Samuni Y, Jacka F, Williams L, O’Neil A, Hayley

AC, Pasço J, Anderson G, Berk M, Maes M. Oxidative & Nitrosative

Stress in Major Depression: Why so much stress? Neurosc Biobeh

Rev. 2014 Sep;45:46-62.

 

53. Morris G, Anderson G, Dean O, Berk M, Galecki P, Martin-Subero M,

Maes M. The Glutathione System: A New Drug Target in

Neuroimmune Disorders. Mol Neurobiol. 2014 Dec;50(3):1059-84.

 

54. Anderson G, Maes M, Kubera M, Berk M. Targetting IL-6 signalling

or IL-6 trans-signalling in depression? Exp Opin Ther Drugs. 2014

May;18(5):495-512.

 

55. Anderson G, Maes M. Metabolic syndrome and mood disorders.

NeuroSci Biobeh Rev. In preparation.

 

56. Anderson G, Maes M. The new serotonin hypothesis of depression

for 2015. NeuroSci Biobeh Rev. In preparation.

 

57. Lucas K, Morris M, Anderson G, Maes M. The Toll Like Receptor

Radical Cycle: a New Drug Target in Immune Related Chronic Fatigue. CNS Neurol Disord Drug Targets. 2015;14(7):838-54.

 

58. Subero MM, Anderson G, Kanchanatawan B, Berk M, Maes M. Comorbidity between

depression and inflammatory bowel disease explained by immune-

inflammatory, oxidative and nitrosative stress, tryptophan catabolite and gut-brain

pathways. CNS Spectrums. 2016 Apr;21(2):184-98.

 

59. Anderson G, Maes M. TRYCAT pathways link peripheral

inflammation, nicotine, somatization and depression in the etiology

and course of Parkinson's disease. CNS Neurol Disord Drug

Targets. 2014 Feb;13(1):137-49.

 

60. Nooripour R, Rezai H, Bakhshani N-M, Anderson G, Maes M.

Effectiveness of Group Counseling Based on a Cognitive-Behavioral

Approach in the Treatment of Aggression in Adolescents. In press.

 

61. Anderson G and Maes M. Co-Enzyme Q10, Depression and

Depression associated conditions. Chapter 13 in Book: Co-Enzyme

Q10: from fact to fiction. Ed: Hargreaves IP.
 

62. Anderson G, Maes M. Obesity and metabolic syndrome: role of

melatonin and mitochondrial regulation. In preparation.

 

63. Galecki P, Talarowska M. Anderson G, Berk M, Maes M. Mechanisms underlying

neurocognitive dysfunctions in recurrent major depression. Med. Sc. Mon. 2015; 21:

 

64. Anderson G, Maes M. The Gut-Brain Axis: The Role of Melatonin in

Linking Psychiatric, Inflammatory and Neurodegenerative

Conditions. Advances In Integrative Medicine. 2015;2(1):31-37.

 

65. Carvalho AM, Anderson G, Berk M. Activation of TH17 cells may

contribute to neuroprogression in depression: proposal of an

integrative model. Neuroscience & Biobehavioral Reviews. In press.

 

66. Anderson G, Maes M. Melatonin in neurodegenerative, psychiatric and systemic

inflammatory disorders. Chapter 8; Pages 179-202 in the Book: Indoleamines: Sources, Role in

Biological Processes and Health Effects. Ed. Angel Catala. Nova Press. 2015.

 

67. Anderson G, Maes M. Bipolar Disorder: Role of Immune Inflammatory Cytokines,

Oxidative and Nitrosative Stress and Tryptophan Catabolites. Curr Psychiatric

Rep. February, 2015. 17.8.

 

68. Anderson G, Maes M. Migraine: the Role of Immuno-inflammation, oxidative and

nitrosative stress and Tryptophan catabolites - Treatment Implications. In press.

 

69. Maes M, Anderson G. Overlapping the Tryptophan Catabolite (TRYCAT) and

Melatoninergic Pathways in Alzheimer's Disease. Curr Pharm Des. In press.

 

70. Anderson G, Maes M. Nicotine dependence and bipolar disorder: possible

biological mechanisms leading to worse outcomes. Curr Mol Med. In press.

 

71. Maes M, Anderson G. Gut Permeability in Stress Related Disorders. Mol

Psychiatry. In preparation.

 

72. Morris G, Cravalho AM, Anderson G, Galecki P, Maes M. The many neuroprogressive

actions of tryptophan catabolites (TRYCATs) that may be associated with the

pathophysiology of neuro-immune disorders. Curr Pharm Des. In press.

 

73. Anderson G. The Gut-Brain Axis: Food As Medicine. Farming Monthly July, 2014

 

74. Anderson G, Markus RP, Rodriguez M, Maes. The Ebola Virus: Melatonin as a readily

available treatment option. J Med Virol, 2015; 87;537-43.

 

75. Anderson G, Rodriguez M. Multiple Sclerosis: The role of Melatonin and N-

acetylserotonin. Multiple Sclerosis & Related Disorders. 2015; 4(2):112-123.

 

76. Anderson G. The Experts Speak: Multiple Sclerosis: The role of Melatonin and N-

acetylserotonin. http://www.vitasearch.com/CP/experts/p2experts.htm

 

77. Anderson G, Maes M. 'A Role for the Regulation of the Melatoninergic Pathways in

Alzheimer's Disease and Other Neurodegenerative and Psychiatric Conditions'

Chap 29; pp 421-44 in Book: " Serotonin and Melatonin: Their Functional Role in Plants and

Implications in Human Health" Editors: Gokare A. Ravishankar and Akula

Ramakrishna. Publishers: Taylor & Francis, India.

 

78. Czarny P , Kwiatkowski D, Toma M, Galecki P, Orzechowska A, Bobinska K, Bielecka

-Kowalska A, Szemraj J, Berk M, Anderson G, Sliwinski T. Single-nucleotide

polymorphisms of genes involved in repair of oxidative DNA damage and the risk of

recurrent depressive disorder. Med Sc Mon. 2016 Nov20;22: 4455-74.

 

 

79. Anderson G, Maes M. Melatoninergic Pathways in Alzheimer's Disease. 2015, Vol. 4, 3-49 In

book: Frontiers in Clinical Drug Research-Alzheimer Disorder. Ed: Atta-Ur-Rahmanr

Bentham Press e-books.

 

 

80. Anderson G, Maes M. Pharmaceutical and nutrition benefits in Alzheimer's disease via

convergence on the Melatoninergic Pathways. Chap 3; 2015; 78:50-127. In book: Frontiers in Clinical Drug Research-Alzheimer Disorder. Ed: Atta-Ur-Rahmanr. Bentham Press e-books.

 

81. Paltsev MA, Polyakova VO, Kvetnoy IM, Linkova NS, Anderson G, Paltseva EM,

Mazzoccoli GM. The unity of pineal gland and thymus signal molecules: role and

significance in aging. Oncotarget. 2016 Mar 15;7(11):11972-83

 

82. Anderson G. Editorial: The Kynurenine and Melatonergic Pathways in Psychiatric and CNS Disorders. Curr Pharm Des. 2016;22(8):947-8

 

83.de Melo LGP, Maes M, Anderson G, Vargas HO, Barbosa DC, Nunes SOV. Interrelated metabolic syndrome, immune-inflammatory and oxidative and nitrosative stress pathways in unipolar and bipolar depression. In press.

 

84. Anderson G, Maes M. Oxidative and Nitrosative Stress, Immune Inflammation and Trptophan Catabolites in Driving Melatoninergic Pathway Alterations in Depression: Treatment Implications. Chap 9; 222-241 in Bk: The Search for Novel Antidepressants: An Integrative View to Drug Discovery. Eds: Reus G, de Quevedo JL, Carvalho AF. 2017

 

85. Slyepchenko A, Maes M, Anderson G, Carvalho AF. Intestinal Dysbiosis, Gut Hyperpermeability and Bacterial Translocation: Missing Links Between Depression, Obesity and Type 2 Diabetes. Curr Pharm Des. 2016;22(40):6087-6106.

 

86. Anderson G. Glia, Immunity and Melatonin. Am J Psychiatry (Lett). In press.

 

87. Anderson G. Role for Melatonin in Psychosis. The Lancet Psychiatry (Lett). In press.

 

88.Roomruangwong C, Kanchanatawan B, Sirivichayakul S, Anderson G, Carvalho AF, Duleu S, Geffard M, Maes M. IgA/IgM responses to tryptophan and tryptophan catabolites (TRYCATs) are differently associated with prenatal depression, physio-somatic symptoms at the end of term and premenstrual syndrome. Mol Neurobiol. 2017 May;54(4):3038-3049.

 

89. Anderson G. Melatonin and Serotonin in Psychiatric and Brain Disorders. Atlas Science, Feb, 2016.

 

90. Anderson G, Vaillancourt C, Maes M, Reiter RR. Breastfeeding and Melatonin: Implications for Improving Perinatal Health. J Breast-feeding Biology. 2016; 1: 8-20.

 

91. de Melo LGP, Nunes SOV, Anderson G, Vargas HO, Barbosa DS, Galecki O, Carvalho AF, Maes M. Shared metabolic and immune-inflammatory, oxidative and nitrosative stress pathways in the metabolic syndrome and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2017 Aug 1;78:34-50.

 

92. Kanchanatawan B, Sunee Sirivichayakul S, Ruxrungtham K, Hemrunroj S, Thika S, Carvalho AF, Geffard M, Anderson G, Maes M. Deficit, but not nondeficit, schizophrenia is characterized by mucosa-associated activation of the tryptophan catabolite (TRYCAT) pathway with highly specific increases in IgA responses directed to picolinic, xanthurenic and quinolinic acid.Mol Neurobiol. 2017 Feb 8. doi: 10.1007/s12035-017-0417-6.

 

93. Kanchanatawan B, Sirivichayakul S, Ruxrungtham K, Carvalho AF, Geffard M, Anderson G, Maes M. Deficit, but not nondeficit, schizophrenia is characterized by a defect in IgM-mediated autoimmune responses directed against noxious tryptophan catabolites (TRYCATs) thereby contributing to increased neuroprogression and associated negative symptoms. Mol Neurobiol. 2017 Mar 14. doi: 10.1007/s12035-017-0465-y.

 

94. Anderson G, Maes M. Alpha 7 Nicotinic Receptor Agonist Modulatory Interactions With Melatonin: Relevance Not Only To Cognition, But To Wider Neuropsychiatric And Immune Inflammatory Disorders. 2016. Vol2, Chap 4; page 186-202; Bk: Frontiers in Clinical Drug Research-Central Nervous System. Bentham Press.

 

95. Slyepchenko A, Maes M, Machado-Veira R, Anderson G, Solmi M, Sanz Y, Berk M, Köhler CA, Carvalho AF. Intestinal Dysbiosis, Gut Hyperpermeability and Bacterial Translocation: Missing Links Between Depression, Obesity and Type 2 Diabetes? Curr Pharm Des. 2016; 22:

 

96. Pinato L, Markus RP, Anderson G. Disrupted nocturnal melatonin rhythm in Autism: correlation with inflammation and sleep disturbances. In press.

 

97. Anderson G. Linking the Biological Underpinnings of Depression: Role of Mitochondria Interactions with Melatonin, Inflammation, Sirtuins, Tryptophan Catabolites, DNA Repair and Oxidative and Nitrosative Stress, with Consequences for Classification and Cognition. Prog NeuroPsyol Pharmacol Bio Psychiatry. 2018 Jan 3;80(Pt C):255-266.

 

98. Kanchanatawan B, Sirivichayakul S, Thika S, Ruxrungtham K, Carvalho AF, Geffard M, Anderson G, Noto C, Maes M. Chronic fatigue and physio-somatic symptoms in schizophrenia are associated with depression and anxiety, neurocognitive deficits and impairments in the tryptophan catabolite pathway. Metab Brain Dis. 2017 Aug;32(4):1003-1016

 

99. Anderson G, Maes M. Depression and Neuroprogression: Sirtuins and Mitochondria as Crucial Hubs. Chap in bk: Neuroprogression and Psychiatric Disorders. Ed Berk M.

 

100. Anderson G, Maes M. Hero and Villain: The Yin and Yang of the Gut in NeuroPsychiatric Disorders. Exp Rev GastroEnterol Hepatol. In press.

 

101. Anderson G, Maes M. How Immune-inflammatory processes link CNS and psychiatric
disorders: Classification and Treatment Implications. CNS & Neurol Disorders Drug Targets. 2017;16(3):266-278.

 

102. Anderson G, Maes M. Oxidative and Nitrosative Stress, Immune Inflammation and Trptophan Catabolites in Driving Melatonergic Pathway Alterations in Depression: Treatment Implications. Chapter 9 in book: Frontiers in Drug Discovery, 2017, Vol. 2, 232-252.

 

103. Kanchanatawan B, Sirivichayakul S, Ruxrungtham K, Carvalho AF, Geffard M, Anderson G, Maes M. Neurocognitive impairments in schizophrenia are strongly associated with negative symptoms and discriminate deficit from nondeficit schizophrenia. In press.

 

104. Moraes JM, Maes M, Barbosa DS, Vargas HO, Anderson G, Carvalho AF, Nunes SOV. Early life trauma, especially emotional abuse, are risk factors for bipolar disorder, major depression, severity and recurrence of illness, suicidal behavior, substance abuse, lowered quality of life, increased disability and oxidative stress. In press.

 

105. Anderson G, Maes M. The Interactions of Tryptophan and its Catabolites with Melatonin and the Alpha 7 Nicotinic Receptor in CNS and Psychiatric Disorders: Role for the Aryl Hydrocarbon Receptor and Direct Mitochondria Regulation. Int J Tryptophan Res. 2017 Feb 16;10:1178646917691738.

 

106. Nunes CS, Maes M, Moraes JB, Bonifacio KL, Vargas HO, Barbosa DS, George Anderson G, Nunes SOB. Lowered quality of life in bipolar disorder and major depressive disorder: predicted by severity of depression, use of mood stabilizers, lower income, early lifetime trauma and increased lipid peroxidation. In press.

 

107. Anderson G, Vaillancourt C, Maes M, Reiter RR. Breastfeeding and the Gut-Brain Axis: Is there a role for Melatonin. BioMolecular Concepts. 2017 Sep 26;8(3-4):185-195.

​

108. Roomruangwong C, Kanchanatawan B, Sirivichayakul S, Anderson G, Carvalho AF, Duleu S, Geffard M, Maes M. IgM-mediated autoimmune responses to oxidative specific epitopes, but not nitrosylated adducts, are highly significantly decreased in pregnancy: association with bacterial translocation, perinatal and lifetime major depression and the tryptophan catabolite (TRYCAT) pathway. Metab Brain Dis. 2017 Oct;32(5):1571-1583.

 

109. Anderson G, Maes M. How Interactions of the Kynurenine and Melatonergic pathways act to modulate Glia-Neuronal interactions in Neuropsychiatric Conditions. Curr NeuroPharm. In press.

 

110. Kanchanatawan B, Sunee Sirivichayakul S, Anderson G, Carvalho AF, Duleu S, Geffard M, Maes M. Natural IgM-mediated autoimmune responses to oxidative specific epitopes, but not nitrosylated adducts, are highly significantly decreased in pregnancy: association with bacterial translocation, perinatal and lifetime major depression and the tryptophan catabolite (TRYCAT) pathway. Metab Brain Dis. 2017 Oct;32(5):1571-1583.

 

111. Roomruangwong C, Kanchanatawan B, Sunee Sirivichayakul S, Carvalho AF, Anderson G, Galecki P, Maes M. Depressive, anxiety and hypomanic symptoms in schizophrenia may be driven by tryptophan catabolite (TRYCAT) patterning of IgA and IgM-responses, with IgA indicating TRYCAT activity and IgM indicating regulatory functions. Prog NeuroPsychoPharm Bio Psychiatry. 2017 Jul 8. pii: S0278-5846(17)30199-9. doi: 10.1016/j.pnpbp.2017.06.033.

 

112. Kanchanatawan B, Sirivichayakul S, Thika S, Ruxrungtham K, Carvalho AF, Geffard M, Anderson G, Noto C, Ivanova R, Maes M. Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway. Metab Brain Dis. 2017 Aug;32(4):1003-1016..

 

113. Gomes C, Martinho F, Barbosa D, Antunes L, Póvoa HC, Baltus T, Morelli N, Vargas H, Nunes S, Anderson G, Maes M. Increased root canal endotoxin levels are associated with chronic apical periodontitis, increased oxidative and nitrosative stress, clinical depression, severity of depression and a lowered quality of life. Mol Neurobiol. 2017 Apr 28. doi: 10.1007/s12035-017-0545-z.

 

114. Potharajaroen S, Tangwongchai S, Tayjasanant T, Thawitsri T, Anderson G, Maes M. Bright light and oxygen therapies decrease delirium risk in critically ill surgical patients by targeting two distinct mechanisms, namely sleep and acid-base disturbances. Psychiatry Res. 2018 Mar;261:21-27.

 

115. Kanchanatawan B, Thika S, Sirivichayakul S, Ruxrungtham K, Carvalho AF, Geffard M, Anderson G, Maes M. Changes in tryptophan catabolite (TRYCAT) pathway patterning are associated with mild impairments in declarative memory in schizophrenia and deficits in semantic and episodic memory coupled with increased false memory creation in deficit schizophrenia. Mol NeuroBio. In press. (2017 Sep 5. doi: 10.1007/s12035-017-0751-8)

 

116. Anderson G. Reciprocal Interactions of Chronic Apical Periodontitis and Depression. Br Dental Journal. In press.

 

117. Kanchanatawan B, Thika S, Gałecki P, Anderson G, Maes M. Affective symptoms in schizophrenia are strongly associated with neurocognitive deficits indicating disorders in executive functions, visual memory, attention and social cognition. Prog NeuroPsychoPharm Bio Psychiatry. 2018 Jan 3;80(Pt C):168-176.

 

118. Roomruangwong C, Cavicchioli FL, Bonifacio K, Barbosa D, Anderson G, Vargas H, Nunes S, Maes M. Impact of comorbid anxiety on major affective disorders: more suicidal attempts, increased recurrence of manic and depressive episodes, higher prevalence of bipolar disorder, more disabilities, and lowered quality of life and serum high-density lipoprotein cholesterol. Psychiatric Res 2017 Nov 8;260:17-23.

 

119. Kanchanatawan B, Sirivichayakul S, Carvalho A, Anderson G, Gałecki M, Maes M. Depressive, anxiety and hypomanic symptoms in schizophrenia may be driven by tryptophan catabolite (TRYCAT) patterning of IgA and IgM responses directed to TRYCATs. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jan 3;80(Pt C):205-216.

 

120. Roomruangwong C, Kanchanatawan B, Sirivichayakul S, Anderson G, Carvalho AF, Duleu S, Geffard M, Maes M. IgA/IgM Responses to Gram-Negative Bacteria are not Associated with Perinatal Depression, but with Physio-Somatic Symptoms and Activation of the Tryptophan Catabolite Pathway at the End of Term and Postnatal Anxiety. CNS Neurol Disord Drug Targets. 2017 Apr 7. doi: 10.2174/1871527316666170407145533.

 

121. Roomruangwong C, Anderson G, Berk M, Stoyanov D, Carvalho A, Maes M. A neuro-immune, neuro-oxidative and neuro-nitrosative model of prenatal and postpartum depression. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Feb 2;81:262-274.

 

 

122. Vargas H, Anderson G, Kubera M, Carvalho A, Nunes S, Moraes J, Roomruangwong C, Bonifacio K, Barbosa D. In major affective disorders, early life trauma predict increased nitro-oxidative stress, lipid peroxidation and protein oxidation and recurrence of major affective disorders, suicidal behaviors and a lowered quality of life. Prog NeuroPsychoPharm Bio Psychiatry. In press.

 

123. Nunes CS, Maes M, Moraes JB, Roomruangwong C, Burm J, Bonifacio KL, Vargas HO, Barbosa DS, George Anderson G, de Melo LP, Drozdstoj S, Moreira E, Carvalho A, Nunes SOB. Lowered quality of life in mood disorders is associated with increased neuro-oxidative stress and basal thyroid-stimulating hormone levels and use of anticonvulsant mood stabilizers. Quality of Life. Submitted.

 

124. Cavicchioli FL, Maes M, Roomruangwong C, Bonifacio KL, Barbosa DS, Anderson G, Vargas HO, Nunes SOV. Associations between severity of anxiety and clinical and biological features of major affective disorders. Psychiatry Res. 2017 Nov 8;260:17-23.

 

125. Kanchanatawan B, Thika S, Anderson G, Galecki P, Maes M. Affective symptoms in schizophrenia are strongly associated with neurocognitive deficits indicating disorders in executive functions, visual memory, attention and social cognition. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jan 3;80(Pt C):168-176.